<DOC>
	<DOCNO>NCT00791999</DOCNO>
	<brief_summary>The objective trial investigate efficacy ( American College Rheumatology 20 % : ACR20 ) superiority two dose regiment CDP870 versus placebo combination MTX active RA patient incomplete response MTX . The pharmacokinetics immunogenicity profile CDP870 also investigate assess extrapolability foreign data Japanese population .</brief_summary>
	<brief_title>Efficacy Confirmation Trial CDP870 add-on Medication Methotrexate ( MTX ) Japanese Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subjects must diagnosis adultonset RA least 6 month longer 15 year duration define 1987 American College Rheumatology classification criterion . Subjects must active RA disease define : At least 9 tender joint 9 swollen joint ESR 30 mm/hour CRP 1.5 mg/dL Subjects must receive treatment MTX least 6 month prior start study drug administration . The dose MTX must remain fixed least 2 month prior study dose MTX within 6 8 mg/week . Patients diagnosis inflammatory arthritis Patients secondary , noninflammatory type arthritis ( eg , osteoarthritis , fibromyalgia ) Patients currently , history , demyelinate convulsive disease central nervous system ( eg , multiple sclerosis , epilepsy ) Patients NYHA ( New York Heart Association ) Class III IV congestive heart failure Patients currently , history , tuberculosis Patients high risk infection ( current infectious disease , chronic infectious disease , history serious infectious disease ) Patients currently , history , malignancy Female patient breastfeed pregnant , childbearing potential Patients previously receive treatment 2 antiTNFα drug previously fail respond treatment 1 aintTNFα drug .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>